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Marijuana use during pregnancy has dramatically increased in recent years, driven in part 
by the increasing legalization of marijuana for medicinal and recreational 
use. However, the impact of prenatal exposure to marijuana on a developing fetus is not 
clear. Previous studies examining this effect have been limited by polysubstance 
use during pregnancy and confounding factors that make data 
interpretation challenging. In this study, we propose a prospective cohort study that will 
address the limitations of prior studies and measure the association between prenatal 
marijuana exposure and adverse neonatal outcomes. Strict exclusion criteria will exclude 
women with tobacco, alcohol or other illicit drug use while pregnant. These insights will 
improve currently available research and enhance evidence-based practice 
recommendations for women who are pregnant or may become pregnant. 
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CHAPTER 1: INTRODUCTION 
1.1 Background  
Across the United States (US), laws surrounding marijuana are rapidly changing. As 
of July 2020, thirty-three states and the District of Columbia (D.C.) have legalized 
marijuana for medicinal use.1 Thirteen of these thirty-three states passed new laws in the 
past five years alone,2 with eleven states and D.C. additionally legalizing marijuana for 
recreational use.1 Although specific laws vary by state, generally marijuana can now be 
used recreationally without a medical prescription. Individuals cannot be ticketed, 
arrested, or convicted for consumption if they adhere to their state laws on required age, 
location, and amount.3 In fifteen other states, marijuana has been decriminalized.1 
Decriminalization reduces penalties for individuals that possess marijuana for personal 
consumption. Rather than criminal prosecution or arrest, possession is treated as a minor 
infraction similar to a traffic violation.3 This recent rise in legalization and 
decriminalization gives reason to believe other states may adopt similar laws in the near 
future.  
Increasing public support for legalization has facilitated the passage of new state 
laws. In 1969, Gallup, a Washington D.C. based analytics company, found public support 
for legalization was 12%.4 By 2018, support had dramatically increased to 66%.4 
Advocates believe marijuana should be legalized because it is a “relatively harmless 
herb” that is natural and safe for consumption.5 Consumers who support this claim 
believe increasing legalization affirms marijuana safety. This belief strikes controversy in 
the public health realm as healthcare providers question the true safety of the drug. 
Presently, marijuana has not been tested for safety or effectiveness. The US Food and 
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Drug Administration (FDA) has not approved marijuana for any indication and warns 
consumers that untested drugs can have unidentified consequences.6 If new state laws 
increase marijuana availability and use, then more patients may be at risk for unknown 
health consequences.  
In particular, one vulnerable population that may be at increased risk is neonates 
exposed to marijuana in utero. This population is often overlooked by advocates as 
neonates are not direct buyers or consumers. However, marijuana has historically been 
the most commonly used illicit drug during pregnancy.7 Expanding legislation has caused 
considerable concern for maternal-fetal medicine as rates of consumption are rising 
among pregnant women. According to the US National Survey on Drug Use and Health, 
marijuana use during pregnancy more than doubled between 2002 and 2017.8 During this 
time, the percentage of women reporting past-month usage increased from 3.4% to 7%.8 
This increase was among women that knew they were pregnant. Researchers are worried 
legalization is creating a false perception of safety for pregnant women.9  
Surveys to ascertain women’s perspectives on marijuana use during pregnancy have 
found mixed feelings and varying levels of concern.7 First, it is important to recognize 
that the majority of pregnant women do not use marijuana. Non-users commonly report 
that it is a dangerous substance that is likely to cause harm to a fetus. These women 
believe there is no safe amount of consumption.10 This perspective is considerably 
different from pregnant women that support use. These women often view marijuana as 
natural and harmless compared to alcohol, tobacco, and other recreational substances 
frequently discouraged while pregnant.7 It is also commonly endorsed as an aid in 
alleviating morning sickness and appetite changes.7 Various reports have found 
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employees of marijuana dispensaries recommend use to pregnant women experiencing 
morning sickness.7 Unfortunately, these recommendations are not evidence-based as no 
studies to date have found marijuana to be effective in managing pregnancy-related 
nausea and vomiting.7 Among marijuana users that quit during pregnancy, cessation in 
the third trimester is often reported. This decision is frequently made as a result of fear of 
drug screening at birth and being reported to child protective services.7 Harm reduction is 
not their primary motivation.7  
Varying perspectives pose a challenge for women seeking guidance during 
pregnancy. Although the majority of women inherently think marijuana is unsafe and will 
discourage use, opposing perspectives from peers, online resources, and discussion 
boards are on the rise. Further complicating the decision-making process is the 
uncertainty that exists in current research. Numerous studies show an increased risk of 
adverse neonatal outcomes while a comparable number of studies show no increased risk. 
Incongruent data makes it difficult for women to determine the true impact marijuana use 
may have on fetal development. This challenge is leaving women frustrated with the 
conflicting information available.7  
Incongruent research has also hindered the development of evidence-based practice 
recommendations. In October of 2017, the American College of Obstetricians and 
Gynecologists (ACOG) released a committee opinion addressing the current issue. This 
report emphasized the unknown fetal consequences, the increasing use among pregnant 
women, and the need for further research. ACOG states ”high-quality studies regarding 
the effects of marijuana and other cannabis products on pregnancy and lactation are 
needed.”11 Until neonatal outcomes become more clear, the official ACOG 
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recommendation for providers is to encourage patients to abstain from all marijuana use 
while pregnant.11 A similar statement from The American College of Physicians was 
released the following year. Addressing the inconsistent information available, it was 
stated that, “An urgent need exists to understand the effects of prenatal marijuana 
exposure, because it may continue to rise in conjunction with the growing acceptance, 
accessibility, and spread of legalization in the United States.”12 More research is urgently 
needed to identify risk during pregnancy and to enhance evidence-based practice 
recommendations.  
 
1.2 Statement of the Problem  
Although diverse patient populations may be at increased risk for unknown health 
consequences associated with marijuana use,13 neonates exposed in utero are particularly 
vulnerable. This population is exposed during critical periods of physical and cognitive 
development,14 which may increase adverse neonatal outcomes at birth. Prior studies 
have demonstrated an increased risk of low birth weight, prematurity, lower Apgar 
scores, and the need for intensive care after delivery. However, despite evidence in 
support of a positive association, study limitations have caused uncertainty. 
One of the most significant limitations is the study population. Existing research is 
profoundly based on patients with polysubstance use. Some studies have reported 
polysubstance use as high as 50% in populations of women using marijuana during 
pregnancy.15 Pregnant women have reported using tobacco, alcohol, cocaine, heroin, 
ecstasy, opiates, and other substances in addition to marijuana.16-18 It is difficult to isolate 
marijuana’s effect in the presence of other substances with known adverse neonatal 
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outcomes. For example, fetal alcohol spectrum disorders have been discussed at length in 
the literature,19 as well as the negative effects of prenatal opioid and tobacco exposure.20 
With polysubstance use, it is challenging to determine whether an association resulted 
from one substance, or is an interaction between multiple. To fully attribute an effect to 
marijuana, it must be analyzed in isolation.  
A second main limitation in current research is sample size. Small sample sizes 
limit statistical power and the strength of an association. This limitation is often a result 
of polysubstance use. Many studies have struggled to identify a patient population using 
exclusively marijuana.21 Consequently, women with alcohol, tobacco, or other drug use 
during pregnancy are often included in sample populations.22 This increases the difficulty 
in data analysis and interpretation of results. Larger sample sizes of independent 
marijuana use are needed to analyze the specific association with adverse neonatal 
outcomes.16  
Although a randomized control trial would provide results with the greatest certainty, 
it is unethical to assign pregnant women to an exposure that may cause harm. That would 
go against the current ACOG recommendation and potentially endanger fetal 
development. A new prospective cohort study addressing past limitations will improve 
currently available research. This will fill the gap in literature and enhance our 
understanding of the true association between prenatal marijuana use and adverse 
neonatal outcomes.  
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1.3 Goals and Objectives 
Consequently, we aim to determine the association between prenatal marijuana 
exposure and neonatal outcomes. More specifically, we will examine whether marijuana 
use independently affects neonatal outcomes at birth. The primary adverse outcome of 
measure will be low birth weight. Women that use tobacco, alcohol, or other illicit 
substances during pregnancy will be excluded from both the exposure and non-exposure 
group. A comprehensive recruitment process will identify women meeting strict criteria 
in a sample size large enough to adequately power our study. 
 
1.4 Hypothesis 
We hypothesize that the proportion of neonates less than 2,500 grams at birth will 
be statistically significantly higher among women that use marijuana during pregnancy 
compared to the proportion of neonates less than 2,500 grams at birth among women that 
do not use marijuana during pregnancy. 
 
1.5 Definitions 
Neonate – newborn less than 28 days old  
Low birth weight – body weight less than 2,500 grams at birth  
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CHAPTER 2: LITERATURE REVIEW  
2.1 Introduction 
 With assistance from the Yale School of Medicine librarians, we conducted a 
systematic search of the literature in July 2019, December 2019, and April 2020. Ovid, 
PubMed, Scopus, and The Cochrane Library were searched using the following 
keywords: cannabis, marijuana, low birth weight, and pregnancy outcome. First, a broad 
search was conducted using ((cannabis) OR (marijuana) AND pregnancy outcome). 
Articles were selected with relevant titles and abstracts. To narrow the search and ensure 
the selection of articles more specific to the primary outcome, we searched ((marijuana) 
OR (cannabis) AND low birth weight). Articles were selected from 1980 to present. We 
also chose resources from the reference lists of studies selected through the initial 
systematic search. This review identified prospective cohort, retrospective cohort, case-
control, and cross-sectional studies, as well as secondary analyses of data, meta-analyses 
and literature reviews. Each selection was analyzed to identify limitations and determine 
how our study can best address gaps in research.   
 
2.2 Marijuana Exposure in Utero  
In the late 1900s, there was a dramatic rise in research on prenatal exposures and 
neonatal outcomes.1 Research began to show that relatively harmless substances for a 
mother could be teratogenic.1 Since this time, numerous studies have specifically 
examined the impact of marijuana use during pregnancy. From this research, ways in 
which marijuana may alter fetal development have been identified.  
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Delta-9-tetrahydrocannabinol, commonly known as THC, is the principal 
psychoactive ingredient in marijuana. THC and its metabolites can cross the placenta and 
be transferred to a fetus in utero.2 This transfer is facilitated by the human 
endocannabinoid system which is responsible for maintaining homeostasis,3 and 
processes of pain, memory, appetite, metabolism, stress, and immunity.4,5 The two main 
receptors, cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2), are 
present in the placenta and fetal brain beginning in early development.6,7 These receptors 
bind endocannabinoids,4 which are natural cannabis-like molecules produced in the 
body.8 Consequently, exogenous cannabinoids such as THC can bind these receptors to 
affect body processes.4 Furthermore, THC can modify placental genes for cell 
morphology, growth, ion exchange and apoptosis,7 which can impair support for a 
growing fetus.1  
Fetal support may also be impaired by carbon monoxide (CO) exposure when 
marijuana is smoked. This exposure reduces blood supply to the placenta and fetal 
oxygenation.9,10 CO from marijuana can reach blood levels five times higher than 
cigarettes.11 Higher levels occur from a greater depth of inhalation, larger puff volumes, 
and longer time holding breath with inspiration.12 These techniques increase the delivery 
of marijuana to the body and the amount of THC that can be transferred to a fetus.   
Further increasing marijuana exposure is its ability to be stored in a mother’s body. 
THC is fat-soluble and can be deposited in body fat after consumption.13 These stores 
continuously release metabolites into the bloodstream,14 prolonging exposure to a fetus.15 
Although a mother may stop marijuana use during pregnancy, her fetus may still be 
exposed for weeks after cessation.  
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Finally, marijuana may increase exposure to other toxins. Marijuana contains the non-
psychoactive ingredient cannabidiol (CBD). CBD can increase the permeability of the 
placenta,16 causing a breakdown of the natural barrier between maternal and fetal 
circulations. This breakdown can increase fetal exposure to other harmful substances that 
may be present in the mother’s body.17 
 
2.3 Prenatal Marijuana Use and Adverse Neonatal Outcomes  
Prior studies analyzing prenatal marijuana exposure have measured various 
neonatal outcomes at birth. Commonly measured outcomes include low birth weight 
(LBW), preterm birth (PTB), small for gestational age (SGA), lower Apgar scores, and 
neonatal intensive care unit (NICU) admission. Research shows marijuana use during 
pregnancy can increase the risk for all five adverse outcomes. 
Low birth weight is the primary outcome of this study because of its strong 
association with morbidity and mortality.18 Neonates less than 2,500 grams at birth are at 
increased risk for respiratory distress syndrome, intraventricular hemorrhage, patent 
ductus arteriosus, necrotizing enterocolitis, retinopathy of prematurity, jaundice, and 
infections during the newborn period.19 Research has also shown an increased risk of 
neurosensory impairments, decreased intelligence quotient (IQ), and lower educational 
achievements later in life.20 These complications can occur in LBW neonates that are 
born preterm or full term. Many studies have found an increased risk of LBW among 
neonates exposed to marijuana in utero. For instance, a retrospective cohort study in 2012 
looked at 24,874 births between 2000 and 2006 at Mater Mothers’ Hospital in Brisbane, 
Australia. Researchers found neonates born to marijuana users were more than twice as 
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likely to be of low birth weight (OR 2.4, 95% CI 2.0-2.9).21 This association remained 
statistically significant after controlling for maternal age, parity, ethnicity, weight, 
cigarette use, alcohol consumption, and illicit drug use (aOR 1.7, 95% CI 1.3-2.2).21 In 
2018, researchers looked at the Colorado Pregnancy Risk Assessment Monitoring System 
from 2014 to 2015. In total, 3,207 deliveries were analyzed. Prenatal marijuana use was 
associated with a 50% increased likelihood of LBW (aOR 1.5, 95% CI 1.1-2.1) after 
adjustment for prenatal tobacco use, maternal age, race, ethnicity, and level of 
education.22 In 2019, a retrospective cohort study looked at 5,343 women between 2011 
and 2016 at two main obstetric hospitals in Washington State. After controlling for 
cigarette, alcohol, and illicit drug use, marijuana use increased the likelihood of having a 
low birth weight neonate by 42% (aOR 1.42, 95% CI 1.01-2.01).23  
In addition to LBW, preterm birth is also associated with morbidity and 
mortality.24 Neonates born before 37 weeks’ gestation are at increased risk for 
intraventricular hemorrhage, neurologic impairment, necrotizing enterocolitis, 
retinopathy of prematurity, and bronchopulmonary dysplasia.25 One of the earliest reports 
of prenatal marijuana use and preterm birth was in 1983. From 1975 to 1981, researchers 
prospectively analyzed 7,301 births at Queen Victoria Hospital in East Grinstead, 
England. Results showed marijuana use more than once a week during pregnancy was 
significantly associated with preterm birth (P=0.0002).26 A later report from 2016 
prospectively looked at spontaneous preterm birth in 5,588 deliveries. Spontaneous 
preterm birth was defined as delivery before 37 weeks’ gestation that was not a result of 
obstetric or medical intervention. Women were selected from centers in Australia, New 
Zealand, Ireland, and the United Kingdom between 2004 and 2011 using the international 
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SCOPE (Screening for Pregnancy Endpoints) study. Researchers found that prenatal 
marijuana use was associated with spontaneous preterm birth independent of cigarette use 
(aOR 2.28, 95% CI 1.49-3.60).27 More recently in 2019, a retrospective cohort study in 
the United States looked at 12,578,557 births between 1999 and 2013. Neonates born to 
marijuana users had increased likelihood of preterm birth (aOR 1.40, 95% CI 1.36-1.43) 
after controlling for maternal age, race, hospital location or teaching, income, insurance, 
multiple pregnancy, pre-existing diabetes mellitus, smoking, hypertension, alcohol 
consumption, and other illicit drug use.17  
To further assess neonates at birth, gestational age and birth weight can be used to 
determine if a newborn is an appropriate size for gestational age. A newborn with a birth 
weight for gestational age in <10th percentile is small for gestational age. Neonates that 
are SGA may have decreased oxygen levels, hypoglycemia, and difficulty maintaining 
body temperature after birth.28 They may also suffer from permanent growth restriction 
and increased risk of sudden infant death syndrome.29 The 2012 retrospective analysis at 
Mater Mothers’ Hospital in Brisbane, Australia found neonates exposed to marijuana in 
utero were more than twice as likely to be in <10th percentile compared to the non-
exposure group (aOR 2.2, 95% CI 1.8-2.7).21 In 2019, a retrospective cohort study in 
Ontario, Canada analyzed 661,617 deliveries between 2012 and 2017. The marijuana 
exposure group had increased odds for being in <10th percentile (RR 1.41, 95% CI 1.36 
to 1.45) and <3rd percentile (RR 1.53, 95% CI 1.45-1.61).30 In 2019, another retrospective 
cohort study in Canada looked at 243,140 pregnancies in British Columbia between 2008 
and 2016. Neonates with prenatal marijuana exposure had increased odds of being in 
<10th percentile (OR 1.65, 95% CI 1.50-1.79).10 This association remained statistically 
 20 
significant after controlling for maternal age, pre-pregnancy body mass index (BMI), 
tobacco use, alcohol use, other substance use, socioeconomic status, race, and ethnicity 
(aOR 1.47, 95% CI 1.33-1.61).10  
Finally, neonates exposed to marijuana in utero have increased risk of lower 
Apgar scores and the need for intensive care after birth. Apgar scores are calculated at 
one and five minutes after delivery. This score assesses newborn appearance, pulse, 
grimace, activity, and respiration. Each category can receive a score from zero to two 
resulting in a total score ranging from zero to ten.31 In 2006, a retrospective cohort study 
looked at 416,834 live births between 1998 and 2002 in Southeast, Australia. Neonates 
born to marijuana users had significantly lower Apgar scores at five minutes compared to 
the non-user group (P<0.001).11 The 2019 retrospective analysis in Ontario, Canada had 
Apgar scores as a second measured outcome. Results showed the marijuana exposure 
group had an increased risk for Apgar scores less than 4 at five minutes (RR 1.28, 95% 
CI 1.13-1.45).30 Results also showed the exposure group had increased risk for neonatal 
intensive care unit admission after delivery (RR 1.40, 95% CI 1.36-1.44).30 NICU 
admission was also measured in the analysis at Mater Mothers’ Hospital in Brisbane, 
Australia. This study showed prenatal marijuana exposure increased odds of NICU 
admission (aOR 2.0, 95% CI 1.7-2.4) after controlling for maternal age, parity, ethnicity, 
weight, cigarette use, alcohol consumption, and illicit drug use.21 
 
2.4 Inconsistency in Existing Research 
Although many studies show a positive association between prenatal marijuana 
exposure and adverse neonatal outcomes, a similar number of studies show a null 
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association. Illustrating the inconsistency in current research is a meta-analysis from 
2016.20 This analysis included one case-control study, one cross-sectional study, and 
twenty-two cohort studies conducted between 1982 and 2014. These studies measured 
birth weight, low birth weight, gestational age, preterm birth, NICU admission, head 
circumference, and neonatal length. Among the 24 studies, each outcome had mixed 
results. To illustrate, low birth weight was measured in seven studies. Two studies 
reported a positive association while five reported a null association. In nine studies 
measuring preterm birth, three showed a positive association while six demonstrated a 
null association. Four studies measured NICU admission after delivery. Three reported a 
positive association while one reported a null association. The remaining outcomes of 
birth weight, gestational age, head circumference, and neonatal length similarly had 
inconsistent findings. Differences in specific findings across studies are likely due to 
variations in sample size, substance use during pregnancy, sample demographics, data 
collection, and statistical analysis. Limitations in these areas will be discussed in detail 
through the remainder of this review. 
 
2.5 Polysubstance Use During Pregnancy 
Women that use marijuana during pregnancy frequently report polysubstance use. 
Most commonly, alcohol and tobacco are reported in addition to marijuana.32-34 Other 
substances such as cocaine, heroin, phencyclidine (PCP), and lysergic acid diethylamide 
(LSD) are reported with less frequency.35 Since polysubstance use is common, studies 
must include a thorough substance use history in sample populations. This is particularly 
important to identify substances known to cause adverse neonatal outcomes. For 
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example, it is well established that alcohol and tobacco exposure during pregnancy 
increase neonatal risk for preterm birth, low birth weight, and being small for gestational 
age.20 Thus, these substances are major confounding factors in studies analyzing the 
association between prenatal marijuana use and these adverse neonatal outcomes. 
Although studies have routinely controlled for these confounders in data analysis, 
researchers have found data interpretation challenging.2 It is difficult to analyze the effect 
of one substance in the presence of others. Multiple substances may have a synergistic 
effect,36 and an individual drug may not be appropriately adjusted for in the statistical 
analysis. Consequently, researchers have found it difficult to fully attribute an outcome to 
marijuana when other substances are present.10 
Despite the challenge polysubstance use creates for data analysis, polysubstance 
users have consistently been included in sample populations.20,37,38 These women are 
often included due to difficulty in finding populations that use marijuana in isolation. A 
retrospective cohort study in 2013 highlights this difficulty.36 In this study, researchers 
found single drug use during pregnancy to be relatively unusual. In their sample, 96% of 
subjects used tobacco in addition to an illegal drug while pregnant. Further highlighting 
the difficulty is the meta-analysis from 2016.20 Participants were included in the analysis 
if marijuana was the only reported illicit drug during pregnancy. For instance, cocaine or 
barbiturate use were exclusion criteria. However, alcohol and tobacco use were not. 
Authors stated “owing to low numbers of studies that account for concurrent cannabis, 
alcohol and tobacco use, studies reporting outcomes of in utero exposure to cannabis in 
the presence of smoking tobacco and consuming alcohol were included.”20  
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Analyses of women using only marijuana during pregnancy are relatively rare. 
Studies that have identified pregnant women without polysubstance use have 
subsequently been limited by sample size. Small sample sizes limit study power and 
create a large margin for statistical error. One study with this limitation is a retrospective 
cohort analysis in 2016. This study found exclusive marijuana use during pregnancy was 
not associated with adverse neonatal outcomes such as low birth weight and preterm 
birth.39 The sample population consisted of 12,069 women that were analyzed between 
2011 and 2015.39 Although the total study population was large, only 106 women were 
marijuana users. Furthermore, 48 women used tobacco in addition to marijuana. This 
created a final sample of only 58 women with exclusive marijuana use during pregnancy. 
Therefore, the sample was too small, and the study was underpowered. A second 
retrospective cohort study analyzed 6,468 women between 2008 and 2011.13 This 
analysis reported mixed results, showing a positive association for NICU admission and 
small for gestational age but a null association for preterm birth. The sample size in this 
study had a larger population of pregnant women without polysubstance use but it was 
too small to adequately power the study.40 This final sample consisted of only 153 
women with exclusive marijuana use during pregnancy. 
Polysubstance use and small sample size are significant limitations in current 
research. Existing studies have not used sampling methods that specifically exclude 
women with tobacco, alcohol, and illicit drug use. Polysubstance users are included in 
data collection and later adjusted for in the statistical analysis. Consequently, samples of 
pregnant women without polysubstance use have been too small within total study 
populations. To reach adequate statistical power, future studies must recruit a larger 
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sample of women with exclusive marijuana use during pregnancy. Until this is 
accomplished, the association will remain uncertain.  
 
2.6 Confounding Variables 
2.6.1 Lifestyle Factors  
 Exercise and body weight are both associated with marijuana use and neonatal 
outcomes at birth. First, marijuana acts as a depressant in the human body.41 It can slow 
normal body processes and reduce physical activity by changing how the brain sends and 
receives signals.41 During pregnancy, regular aerobic and strength-conditioning exercises 
are frequently encouraged.42 In uncomplicated pregnancies, moderate exercise for 20-30 
minutes on most or all days of the week can improve fitness, aid in weight management, 
and reduce the risk of gestational diabetes.42 Pregnant women that do not exercise, or 
have reduced physical activity, may not achieve these benefits.  
Second, marijuana can affect body weight and body mass index by altering an 
individual’s diet. Marijuana use can lead to irregular eating patterns and poor nutritional 
intake.41 Body mass index measures body fat through a calculation using height and 
weight.43 The four BMI categories are underweight (<18.5), normal weight (18.5-24.9), 
overweight (25-29.9), and obese (30 or higher).43 Pre-pregnancy BMI is an important 
measure to assess risk during pregnancy. Women that are underweight, overweight, or 
obese at conception have a higher risk for adverse maternal and neonatal outcomes 
compared to women of healthy weight. For example, women with a BMI <18.5 are at 
increased risk for preterm birth and having a neonate with a LBW.44 Women with a BMI 
over 25 are at increased risk for preterm birth, high blood pressure, gestational diabetes 
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and having a baby that is large for gestational age (LGA).45 A large for gestational age 
neonate has a birth weight for gestational age in >90th percentile.46  
Lastly, pre-pregnancy BMI is used to determine an appropriate gestational weight 
gain. Weight gain guidelines are published by the Institute of Medicine (IOM). Following 
these guidelines, total weight gain should be 28-40 pounds for underweight women, 25-
35 pounds for normal-weight women, 15-25 pounds for overweight women, and 11-20 
pounds for women that are obese.47 Weight gain outside the recommended ranges can 
affect the immediate and future health of a mother and her newborn. Evidence shows 
inadequate gestational weight gain can lead to decreased birth weight while excessive 
weight gain can lead to increased birth weight.47 Since gestational weight gain, pre-
pregnancy BMI, and exercise can affect neonatal outcomes, prior studies analyzing 
prenatal marijuana use have controlled for these factors in the statistical analysis.22,48  
 
2.6.2 Psychosocial Factors 
Intimate partner violence, pregnancy intention, and maternal stress can increase 
the risk of adverse neonatal outcomes. First, illicit substance use has been associated with 
increased rates of physical abuse.49 Women using marijuana or illicit substances during 
pregnancy may be at increased risk for intimate partner violence. Physical trauma while 
pregnant increases the risk of adverse neonatal outcomes such as preterm birth and low 
birth weight.50 To control for intimate partner violence, women are asked to self-report 
physical abuse during pregnancy. In 2018, a retrospective cohort study accomplished this 
by asking participants, “During your most recent pregnancy, did your husband or partner 
push, hit, slap, kick, choke, or physically hurt you in any other way?”51 If women 
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responded “yes,” they were classified as having experienced intimate partner violence. 
This was then controlled for in the statistical analysis.  
 In addition to physical trauma, maternal stress is a well-established risk factor for 
preterm delivery.52 One source of maternal stress during pregnancy can be pregnancy 
intention. Unintended pregnancies are believed to be inherently more stressful than 
planned pregnancies. Researchers obtain this information through self-report. The 2018 
retrospective analysis that assessed intimate partner violence also assessed pregnancy 
intention. Researchers asked women if their current pregnancy was intended or 
unintended.51 Another report in 2018 recorded more detailed responses from 
participants.22  Women were asked the question “Thinking back to just before you got 
pregnant with your new baby, how did you feel about becoming pregnant?” If women 
responded with “I wanted to be pregnant later,” “I didn’t want to be pregnant then or at 
any time in the future,” or “I wasn’t sure what I wanted,” then they were categorized as 
an unintended pregnancy in the statistical analysis. 
Overall, many factors can impact maternal stress during pregnancy. It would be 
unrealistic to aim to assess every possible factor for each patient. A more realistic 
approach is to assess stress levels as a whole. In 2008, a brief version of the Pregnancy 
Experience Scale (PES) was studied in a population of 112 pregnant women.53 This scale 
measures frequently endorsed pregnancy hassles and uplifts using a 4-point Likert scale. 
In this study, the scale was completed five times between 24- and 38-weeks’ gestation. 
Results showed the brief version of the scale had internal reliability, test-retest reliability, 
and convergent validity comparable to the long version. Researchers concluded the PES-
Brief is a cost-effective tool to assess stress and emotional valence in pregnancy.53 This 
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scale can be used to assess maternal stress when analyzing prenatal marijuana use and 
adverse neonatal outcomes. 
 
2.6.3 Prenatal Care  
Prenatal care plays an important role in pregnancy management and neonatal 
outcomes. Some studies have found women that use marijuana during pregnancy are less 
likely to receive adequate prenatal care compared to women that do not use marijuana 
during pregnancy.15,54 Regular visits help prevent complications and inform women on 
steps to take to promote a healthy pregnancy. These visits are also essential for education 
on substance use. To analyze differences in prenatal care between exposure and non-
exposure groups, prior studies have used The Kotelchuck Index, also known as the 
Adequacy of Prenatal Care Utilization (APNCU) Index.22,55  
The Kotelchuck Index uses two independent dimensions to characterize adequacy 
of prenatal care utilization: Adequacy of Initiation of Prenatal Care and Adequacy of 
Received Services. The first dimension characterizes the adequacy of when prenatal care 
began. The second dimension characterizes the adequacy of the total number of visits 
received. The expected number of prenatal care visits is determined by the ACOG 
recommendation schedule. For uncomplicated pregnancies, ACOG recommends a 
prenatal care visit once a month between weeks 4 and 28, twice a month between weeks 
28 and 36, and once a week from 36 weeks to birth.56 This information can be used to 
calculate adequacy. Depending on the proportion of observed visits to expected visits, 
care is classified as inadequate (<50%), intermediate (50-79%), adequate (80-109%) or 
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adequate plus (110% or more).57 This index does not assess the quality of care received, 
but simply its utilization.  
 
2.6.4 Maternal Data  
 Maternal characteristics can be mediating factors of both substance use and 
neonatal outcomes at birth. These characteristics include age, race, ethnicity, parity, prior 
preterm birth, prior low birth weight infant, marital status, education level and income. 
Recipient of Medicaid and/or Women, Infants, and Children (WIC) can also be a factor. 
WIC is a special supplemental nutrition program that provides supplemental foods, 
healthcare referrals and nutrition education to pregnant and postpartum women, infants 
and children to the age of five.58  
 Maternal age can increase the risk of low birth weight and preterm birth. This is 
particularly seen among women less than 15 and greater than 35 years old.59,60 Race and 
ethnicity can also increase the risk of preterm birth. For example, in 2018 the preterm 
birth rate among African American women was 14%. That same year, the rate among 
white women was only 9%.61 Women with a prior preterm delivery are also at increased 
risk for a subsequent preterm birth.62 Higher maternal parity and a history of a low birth 
weight neonate increase the risk for future low birth weight.63  Marital status during 
pregnancy may indicate a level of support or an area causing increased maternal stress. 
Other characteristics such as education level, income, Medicaid recipient, or WIC support 
can be indicators of the resources available to women during pregnancy. These factors 
have frequently been cited in prior studies analyzing prenatal marijuana exposure.21-23 
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2.7 Relevant Methodology 
2.7.1 Marijuana Drug Testing  
There are several ways to identify marijuana use in patient populations. Prior 
studies have used maternal self-report, urine drug screens (UDS), fetal meconium assays, 
maternal serum assays, and the presence of THC in umbilical cord homogenate. 
Maternal self-report has been a common method used to identify marijuana use 
during pregnancy. Information can be gathered through patient interviews or 
questionnaires to obtain immediate results. Prior studies have identified users by asking 
drug use directly,27 or using medical record documentation from prenatal care visits.30 
Although this is a common method, it is a frequently documented limitation in research 
design.38 Reliance on self-report alone is likely to underestimate the true prevalence of 
marijuana use in a patient population. Fear of legal consequences or being reported to 
child protective services64 can cause reporting bias.51 Regardless of the rationale, 
marijuana use is under-reported and risks misclassifying exposure subjects into the non-
exposure group. This misclassification can bias results towards the null and potentially 
mask a true association.51 Another limitation of self-report is recall bias.38 Patients may 
under or overestimate marijuana use when recalling frequency or quantity in weeks prior. 
This is a particular concern in studies stratifying participants to analyze dose-dependent 
relationships. Without accurate recall, dose-related associations cannot be determined. 
Urine drug screens are the most commonly used drug test.65 They are an objective 
measure of drug use and are often preferred over subjective self-reports. They are readily 
available, easily collected, and non-invasive.65 A commonly cited limitation for UDS is 
the timing of testing. For frequent users, marijuana can be detected up to thirty days. For 
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less frequent users, a UDS may only be positive for one to three days.66 Time restraints 
limit the utility of these tests to frequent or recent users. Patients may wait to take a UDS 
until they have passed the positive testing window. To limit this evasion, tests must be 
given at regular intervals in high-risk populations.23 This may reduce the risk of 
misclassifying users as non-users from a single or infrequent urine drug screen.  
One study in 2019 looked at the use of UDS with maternal self-report.67 The 
composite study outcome included spontaneous PTB, stillbirth, SGA, and hypertensive 
disorders of pregnancy. When using a UDS and maternal self-report to identify the 
exposure group (n = 211), marijuana use during pregnancy was associated with increased 
risk for the primary composite outcome. When the analysis was repeated using self-report 
alone, there was no association. Self-report alone only identified 18 of the 211 (8.5%) 
marijuana users in the sample population. The remaining 193 women were identified 
from a positive urine drug screen. This change in association emphasizes the role of 
biological testing. Without the objective measure, participants were misclassified into the 
non-exposure group and the association was biased towards the null.67 Studies that use 
subjective self-report alone have a high risk of misclassification. 
For newborn drug screening, fetal meconium assay is the current gold standard.65 
It is the most sensitive tissue to evaluate fetal drug exposure65 because it contains 
metabolic waste products from exposures in utero. Meconium is the first bowel 
movement passed by a fetus, typically within the first couple of days after birth. Although 
it is the gold standard, it is not without limitation. First, meconium begins to form in the 
second trimester of pregnancy when the fetus’ swallowing reflex develops. This 
inherently limits meconium assay to exposures in the second or third trimester. Exposures 
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during the first trimester will not be present in meconium. Second, meconium may be 
passed in utero before a sample can be collected after birth. In utero passage is 
unpredictable and limits reliance on meconium assay as a primary testing method. Third, 
drugs given during labor can be transferred to a fetus and passed in meconium. This may 
alter meconium assays and confound results. Lastly, meconium sampling cannot be 
obtained throughout pregnancy. This method can only identify drug exposure after birth.  
Umbilical cord testing is similarly limited to post-delivery analysis and is less 
frequently used. Challenges arise from obtaining adequate cord samples with variable 
timing and location of birth. However, this method has demonstrated strength in objective 
testing. A recent analysis in 2017 used umbilical cord homogenate to confirm self-
reported drug use.68 Results showed a poor correlation between self-report and objective 
testing. This was similar to a study in 1995 that used maternal serum assay to confirm 
self-reports. Researchers found that 69% of positive serum assays were from participants 
that denied marijuana used in structured interviews.35 Serum assays are more invasive 
and less frequently used but further demonstrate the crucial role in biological testing. 
They can be used throughout pregnancy and are not limited to post-delivery analysis.  
With increasing legalization, accuracy in self-reported drug use may increase. 
Decreased fear of legal consequences may allow more pregnant women to share their true 
marijuana use history. However, self-report alone remains to have the highest risk for 
exposure status misclassification. Future protocols need to incorporate biological testing 
in research designs to increase the accuracy of exposure status.  
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2.7.2 Marijuana Use Patterns  
 Currently, there is no reliable way to quantify marijuana use through biological 
testing.38 Researchers must rely on self-report to identify frequency or quantity of 
consumption. Prior studies analyzing dose-dependent relationships show the quantity of 
marijuana is likely a contributing factor in neonatal outcomes.13 For example, a 
prospective cohort study in 1984 found marijuana use six or more times per week was 
associated with a reduction in length of gestation.69 This was seen after controlling for 
nicotine, alcohol, parity, pre-pregnancy weight, and sex of the infant. A later meta-
analysis in 1997 evaluated ten studies on neonatal birth weight.34 Results showed 
marijuana use at least four times per week was associated with a reduction in mean birth 
weight. 
 Various reports have taken different measures to quantify marijuana use. One of 
the earliest reports in 1983 retrospectively asked participants if average marijuana 
consumption during pregnancy was occasional, weekly, or daily.70 This was the only 
question participants were asked. Researchers recognized this was an early report on 
patterns of use and data was poorly quantified. Future studies were encouraged to ask 
more detailed questions. 
A report three years later at Yale New Haven Hospital assessed frequency with 
greater detail. Women were interviewed within a few weeks of their first prenatal care 
visit. Marijuana users were asked to report average use. Responses ranged from “less 
than once per month but once since pregnant” to “five or more times daily.”71 
Participants were then categorized as non-users, occasional users, or regular users. 
Occasional use was once per month or less, while regular use was two to three times per 
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month or more. These interviews were the only time marijuana use was assessed. 
Researchers encouraged future studies to collect data several times during pregnancy.  
 In 2010, a prospective cohort study collected data on marijuana use in each 
trimester.72 Women were asked to report marijuana consumption through the number of 
joints used. If women used bowls or blunts, they were asked to convert this amount to an 
equivalent number of joints. If they were unsure of the conversion, a bowl would convert 
to three joints and a blunt would convert to four joints. This conversion provided a more 
detailed report on marijuana smoked during pregnancy. Prior studies have focused on 
smoking since it is the most common method of use.73 However, with growing 
legalization, marijuana is now more readily available in vapor and oral forms. Future 
studies analyzing dose-dependent relationships will have to gather information on these 
other forms as well. 
 
2.7.3 Sampling and Recruitment 
 Prior studies looking at the association between marijuana use and neonatal 
outcomes have used consecutive convenience sampling to recruit study participants.14 
This was the sampling method in the prospective cohort study at Yale New Haven 
Hospital.71 This study used all women presenting for their first prenatal care visit at a 
private obstetric or midwifery practice, health maintenance organization or hospital clinic 
in New Haven, Connecticut. Women were selected if they intended to deliver at Yale 
New Haven Hospital. Using this method, 6,219 women were approached about the study 
over two years. In this sample, 3,857 women met the inclusion criteria and 367 were 
identified as marijuana users. Consecutive convenience sampling can be used in future 
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studies analyzing exclusive marijuana use during pregnancy. Since polysubstance use is 
common, approaching all women presenting for a first prenatal care visit can increase the 
likelihood of identifying an adequate sample of women with exclusive marijuana use.  
 
2.7.4 Participant Population Criteria  
 Exclusion criteria from the literature have included multiple birth pregnancies, a 
known congenital or chromosomal fetal anomaly, stillbirth, underlying maternal medical 
conditions that increase risk during pregnancy, and maternal age <18 due to the need for 
parental consent.68,72,74 A woman with a multiple pregnancy is often excluded because it 
is a strong risk factor for preterm birth, and more than 50% of women with twins deliver 
before 37 weeks’ gestation.75 Specific medical conditions are chronic hypertension or 
heart disease requiring medication, diabetes, renal disease, systemic lupus erythematosus, 
antiphospholipid syndrome, sickle cell disease, human immunodeficiency virus (HIV), 
previous cervical knife cone biopsy, 3 or more pregnancy terminations, and 3 or more 
miscarriages. 27,35,48 These conditions put patients at high risk for preterm birth and 
having newborns that are SGA.48 Women that use opioids, methadone, amphetamines, 
benzodiazepines, and barbiturates during pregnancy have also been excluded to varying 
degrees. These substances as well as tobacco, alcohol, and illicit drugs can be 
confounding factors for adverse neonatal outcomes. Inclusion criteria have required 
participants to have all neonatal outcome variables available after birth.  
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2.7.5 Statistical Analysis 
 A recent study in 2020 reported a positive association between prenatal marijuana 
use and low birth weight (OR 1.82, p<0.001).76 In the non-marijuana exposed group 
(n=531), 11.5% had a low birth weight. In the marijuana exposed group (n=531), 20.9% 
had a low birth weight. This produced an effect size of 9.4%.76 Exposure and non-
exposure groups were closely matched for delivery year, delivery hospital, maternal age, 
maternal marital status, race, parity, medical insurance, smoking status, alcohol use, 
benzodiazepine use, and opioid use. This effect size can be used to calculate sample sizes 
in future study designs. As one of the most recent reports on prenatal marijuana use, this 
study more closely measures the effect of marijuana at its increased potency compared to 
the past. 
 
2.8 Evolving Marijuana Climate  
The current climate surrounding marijuana use in the US has significantly 
changed over the past 50 years. Not only have there been societal shifts in moral and 
legal acceptability,23 but the composition of the drug itself has changed. Advances in 
breeding and greenhouse technology have increased marijuana concentrations.77 Potency 
is determined by the ratio of THC to CBD. CBD is a non-psychoactive ingredient that 
can lessen the effect of THC.78 Thus, increasing CBD in marijuana will lower the ratio of 
THC to CBD and decrease overall drug potency. Similarly, decreasing CBD and 
increasing THC will increase potency. Since the 1970s, marijuana potency has increased 
six to seven-fold.22  
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Current research is profoundly based on marijuana use of lower potency,38 in an 
era of lower public support, and less frequently reported use. Research relying on self-
reports in a time of lower acceptance increases the risk for social desirability bias and 
reduces the accuracy of exposure status. New state laws and public acceptance may allow 
researchers to better estimate the true prevalence of a patient population. This may reduce 
bias and exposure group misclassification. It may also aid in measuring the potential 
effects of increased potency. In 2019 alone, six retrospective studies found a positive 
association between prenatal marijuana use and adverse neonatal outcomes.10,17,23,30,67,79 
In 2020, a newly released study found an increased rate of low birth weight (OR 1.82), 
preterm delivery (OR 1.79), NICU admission (OR 1.43), and lower APGAR scores 
(p=0.004).76 These more recent reports may represent adverse neonatal outcomes of 
present-day marijuana use during pregnancy. 
 
2.9 Conclusion  
The current literature on prenatal marijuana use and adverse neonatal outcomes 
shows an increased risk for low birth weight, preterm birth, SGA, lower Apgar scores, 
and NICU admission. These associations are not, however, unequivocal since a similar 
number of studies show a null association. Existing research is limited by polysubstance 
use, small sample size, self-reporting bias, recall bias, and inadequate information on 
quantification. The inconsistency may also be arising from research conducted in an era 
of lower social acceptance, less legalization, and decreased potency. Our proposed 
prospective cohort study will fill this current gap in research. We will exclude 
participants with polysubstance use, recruit a sample size to reach adequate statistical 
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power, use urine drug screens in addition to self-report, and obtain detailed quantification 
data to analyze a dose-dependent relationship.   
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CHAPTER 3: METHODS 
3.1 Study Design 
 We propose a prospective cohort study analyzing the effect of prenatal marijuana 
exposure on select neonatal outcomes, compared to matched subjects without marijuana 
exposure in utero. Pregnant women will be age-matched. Researchers collecting neonatal 
outcomes at birth will be blinded to exposure status. 
 
3.2 Study Population and Sampling 
The source population will be pregnant women in Boston, Massachusetts where 
recreational marijuana was legalized in 2016. Women will be identified using 
consecutive convenience sampling. All pregnant women presenting for their first prenatal 
care visit in a private or public obstetric practice, midwifery practice, or hospital clinic in 
Boston that plans to deliver at Brigham and Women’s Hospital or Massachusetts General 
Hospital will be asked to participate. 
 Women will be asked to participate if they have a singleton pregnancy with an 
expected due date in our study period. They must also agree to regular urine drug screens 
and reporting daily marijuana use. Exclusion criteria will be polysubstance use (tobacco, 
alcohol, illicit drugs, opioids, methadone, amphetamines, benzodiazepines, and 
barbiturates), multiple-birth pregnancy, maternal age <18, a known congenital or 
chromosomal fetal anomaly, stillbirth or underlying medical condition (chronic 
hypertension or heart disease requiring medication, diabetes, renal disease, systemic 
lupus erythematosus, antiphospholipid syndrome, sickle cell disease, human 
immunodeficiency virus (HIV), previous cervical knife cone biopsy, 3 or more pregnancy 
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terminations, and 3 or more miscarriages). Women with any other medical condition 
requiring medicinal marijuana will also be excluded. This will reduce the inclusion of 
women with medical conditions that may increase the risk of adverse neonatal outcomes. 
After meeting the study criteria, exposure group participants will be age-matched to non-
exposure group participants.  
 
3.3 Recruitment 
We will recruit women at their first prenatal care visit. Patients will be screened 
by their healthcare providers to determine eligibility based on inclusion and exclusion 
criteria. If women agree to participate, they will be contacted by a researcher to describe 
study expectations and to obtain written consent. After receiving consent, we will search 
patients’ medical records to confirm eligibility. Eligible participants will then be given 
the first urine drug screen and complete the first participant survey. After identifying the 
sample of women with marijuana use, a researcher will provide instructions on how to 
report daily marijuana consumption. As an incentive, a $25 visa gift card will be given to 
every participant at the completion of the study. 
 
3.4 Subject Protection and Confidentiality  
 Massachusetts General Hospital and Brigham and Women’s Hospital are a part of 
the Partners Healthcare network. The institutional review board of Partners Healthcare is 
the Partners Human Research Committee. For our study, we will seek an ethical review 
by the Partners Human Research Committee and the Human Investigation Committee of 
Yale University School of Medicine. If approved, written informed consent (Appendix 
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D) will then be obtained from all women before study data is gathered. Each participant 
will be assigned an identification code that will be used on all data collection forms and 
in the statistical analysis. 
 
3.5 Study Variables and Measures 
3.5.1 Independent Variable 
 The independent variable is marijuana exposure in utero. This will be 
operationalized as maternal marijuana use once or more during pregnancy. Daily 
marijuana use will be self-reported, and participants will have a urine drug screen at each 
prenatal care visit. Any other drug use from the exclusion criteria list will warrant 
removal from the study.  
 
3.5.2 Dependent Variable 
 The primary dependent variable is low birth weight. This is a dichotomous 
outcome. Neonates less than 2,500 grams at birth will be classified as LBW, while 
neonates greater than 2,500 grams at birth will not be classified as LBW.  
 There are four secondary outcomes of interest. The first is spontaneous preterm 
birth which is a dichotomous variable. Neonates born before 37 weeks’ gestation will be 
classified as preterm, while neonates born after 37 weeks’ gestation will be classified as 
full term. The second outcome is small for gestational age which is also a dichotomous 
variable. Neonates less than the 10th percentile will be classified as SGA. Neonates above 
the 10th percentile will not be classified as SGA. Our last dichotomous secondary 
outcome will be NICU admission. This will include neonates that require intensive care 
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during the hospital admission immediately following birth. Our final secondary outcome 
is Apgar scores. This is an ordinal variable measured from 0-10. 
 
3.5.3 Potential Confounding  
 Neonatal outcomes at birth can be affected by many factors during pregnancy. 
Potential confounding factors we will control for are maternal age, race, ethnicity, marital 
status, parity, pregnancy intention, prenatal care, prior preterm birth, prior LBW neonate, 
pre-pregnancy BMI, gestational weight gain, exercise, maternal education, Medicaid 
and/or WIC recipient, income level, intimate partner violence, and overall stress. In our 
cohort, the exposure and non-exposure groups will be age-matched. All confounding 
variables will be assessed in a participant survey (Appendix A). 
 Pregnancy intention will be categorized based on response to the question “How 
did you feel when you first found out you were pregnant?” Answer choices are adapted 
from prior studies.1,2 Women that respond with “I wanted to be pregnant at a later time,” 
“I don’t want to be pregnant now or at any time in the future,” and “I’m not sure what I 
wanted,” will be classified as an unintended pregnancy. If women select the fourth 
answer choice of “I wanted to be pregnant now,” then they will be categorized as an 
intended pregnancy. Multiparous women that cannot recall gestational age or birth weight 
from a prior delivery can select “I am not sure” on the survey. Researchers will gather 
this data from medical records for all participants to ensure accuracy. Prenatal care 
adequacy will be determined through the Kotelchuck Index (Appendix C), assessed after 
the last prenatal care visit. Exercise is described as 30 minutes of moderate-intensity 
aerobic activity. To be adequate, it should be done on 5 or more days each week. Intimate 
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partner violence screening has been adapted from a prior report.3 If women report being 
pushed, tripped, hit, slapped, kicked, choked, or physically hurt in any other way during 
pregnancy, they will be categorized as having experienced intimate partner violence. 
Overall stress will be measured using the brief version of the Pregnancy Experience Scale 
(Appendix A). The brief version has a 4-point Likert scale for ten of the most commonly 
reported uplifts and ten of the most commonly reported hassles during pregnancy.4 This 
scale is included in the participant survey. 
Characteristic Variable Description 
Maternal   
Race  Categorical American Indian or Alaska Native, Asian, 
Black or African American, Native Hawaiian 
or Other Pacific Islander, White 
Ethnicity Categorical Hispanic or Latino, Not Hispanic or Latino 
Marital Status Categorical Single, Married, Separated, Divorced, Widow 
Parity Ordinal 0, 1, 2, 3 or more  
Pregnancy Intention Dichotomous Intended, Unintended  
Prenatal Care Ordinal Inadequate, Intermediate, Adequate, 
Adequate Plus  
Prior Preterm Birth Dichotomous Prior PTB, No Prior PTB 
Prior LBW Neonate Dichotomous Prior LBW Neonate, No Prior LBW Neonate 
Pre-pregnancy BMI Ordinal  Underweight, Normal, Overweight, Obese 
Gestational Weight Gain Ordinal  Below, Within or Above IOM 
Recommendations 
Exercise  Dichotomous Adequate: ≥5 days/week 
Inadequate: <5 days/week 
Education Ordinal  Completed: < high school, High School or 
GED, Higher Education/College 
Medicaid Recipient Dichotomous  Primary insurance (yes/no) 
WIC Recipient Dichotomous Recipient (yes/no) 
Income Level Ordinal  <185% FPL, 185-250% FPL, 250-400% FPL, 
>400% FPL 
Intimate Partner Violence Dichotomous  Experienced Violence, 
Did Not Experience Violence 
Stress Level Ordinal  PES Brief - Likert Scale 
 
Table 1. Descriptive Characteristics of Study Population  
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3.6 Additional Methodology Considerations 
Marijuana use history will be determined by maternal self-report and urine drug 
screens. This information will be obtained and updated at every prenatal care visit. We 
will use urine drug screens because they are less expensive and non-invasive compared to 
maternal serum assays. If women report marijuana use or have a positive urine drug 
screen, they will be asked to report their daily consumption. Reporting this information 
daily will reduce bias from asking participants to recall use during each prenatal care 
visit. It is difficult to accurately report prior behavior that can change over time (i.e. may 
vary from week to week). Although self-reporting is not an objective measure of use, it is 
the only method to obtain frequency and quantity of consumption. Conducting the study 
in Boston, Massachusetts where recreational marijuana is legal, may reduce social 
desirability bias that could occur in an area without legalization.  
Participants will receive daily text messages to report marijuana use. Standard text 
messages will ask the method and amount of consumption. First, a text message will ask 
“Did you use marijuana today?” If the reply is “No” then no further message will be sent. 
If the reply is “Yes” then a message saying, “What method did you use and how much 
did you consume?” will be sent. Methods will include smoking, vaping, and oral 
consumption. Participants can report the number of bowls, blunts, joints, or grams of 
marijuana that was smoked. From these reports, all consumption will be converted to 
grams. To start, a bowl will convert to 3 joints, and a blunt will convert to 4.5 The total 
number of joints will then be converted to grams. On average, one joint contains 0.66 
grams of marijuana.6 This will be the conversion for participants that do not directly 
report their use in grams. For participants that vape, the number of oil cartridges used and 
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the number of grams from each cartridge will be recorded. Lastly, oral consumption will 
be reported in grams. If edibles are made by the participant, they will be asked to measure 
the marijuana content in the recipe. If edibles are purchased, they can gather this 
information from the seller or product packaging. Since Massachusetts has marijuana 
dispensaries, weight in grams can more easily be identified. Participants that purchase 
marijuana with packaging will be asked to include packaging data. The text message data 
software will be selected at the beginning of this study based on the resources available. 
Additionally, marijuana use journals (Appendix B) will be provided to participants that 
wish to keep a written history of use. These journals will also guide participants on how 
to most accurately report quantity of use and will be explained in detail by the research 
assistants at the beginning of the study. 
At the end of pregnancy participants will be stratified by total consumption, 
frequency of use and timing of exposure. For total consumption, each participant will be 
stratified by total grams consumed. For frequency of use, women will be stratified into 
four categories. The four categories will be of no use, light use, moderate use, and heavy 
use. Light use will be once per month or less. Moderate use will be 2-4 times per month 
and heavy use will be 4 times per month or more. Total consumption and frequency will 
be used to analyze a potential dose-dependent relationship. Lastly, women will be 
stratified by timing of exposure. This analysis will measure a potential association 
between trimester of use and adverse neonatal outcomes.  
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3.7 Data Collection  
 For our study, we will use a survey to collect information on maternal age, race, 
ethnicity, marital status, parity, pregnancy intention, prenatal care, prior preterm birth, 
prior LBW neonate, pre-pregnancy BMI, gestational weight gain, exercise, education, 
Medicaid, WIC, income, intimate partner violence and overall stress (Appendix A). This 
information will be used to analyze descriptive and confounding factors. The first survey 
will be given by a researcher to guide patients and answer any questions that arise. 
Subsequent surveys will be given by research assistants. The same survey will be given at 
each prenatal care visit to update any changes since the patient was last seen. If a research 
assistant cannot attend a prenatal care visit, the survey can be administered over the 
phone. 
 Drug use information will be collected at each prenatal care visit as well. The 
participant survey will include a substance use history where the mother can self-report 
drug use. Urine drug screens at each visit will objectively test for THC, amphetamines, 
cocaine, opiates, PCP, barbiturates, benzodiazepines and methadone. Urine samples will 
also be tested for recent tobacco and alcohol consumption. The information collected for 
this study will be confidential and not disclosed to providers. However, providers can 
screen patients at their own discretion and patients can disclose their marijuana use 
history directly.  
 After birth, information on neonatal outcomes will be collected from medical 
records. Birth weight, gestational age, Apgar scores, and NICU admission can be easily 
obtained from neonatal medical charts. Birth weight and gestational age can be used to 
calculate if a neonate is SGA, if this information is not already documented in the 
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medical record. Brigham and Women’s Hospital and Massachusetts General Hospital 
both use Epic electronic medical records which will provide easy remote access for 
researchers obtaining birth outcomes. The research assistants assigned to neonatal record 
retrieval will be blinded to exposure status. 
 
3.8 Sample Size Calculation  
 Our study is designed to measure the association between prenatal marijuana 
exposure and adverse neonatal outcomes at birth. Our primary outcome is low birth 
weight. One of the most recent reports analyzing this association found a low birth 
weight among 11.5% of non-users and 20.9% of marijuana users.7 Using this effect size 
of 9.4%, a significance level of 0.05 (α), and 80% power, we calculated a minimum 
sample size of 480 participants. This yields a sample of 240 women in the exposure 
group and 240 women in the non-exposure group (Appendix E). This calculation is 
derived from the algorithm by Power and Precision version 4.0 software (BioStat Inc.).  
We will sample beyond the minimum sample size in anticipation of drop out and 
women meeting exclusion criteria at some point after their initial presentation. Prior 
studies have experienced up to 15% loss of participants in their total sample population.5,8 
To account for 15% loss during the study period we will obtain a sample size of 552 




3.9 Statistical Analysis 
 First, exposure and non-exposure group participants will be age-matched. Then, 
confounding factors described as ordinal variables will be analyzed using paired t-tests, 
while confounding factors described as categorical or dichotomous variables will be 
analyzed using Chi-squared tests. Confounding variables that will be tested can be found 
in Table 1. We will examine the association of each confounder with the exposure and 
outcome. Confounders that meet a significance threshold of p<0.1 will be included in our 
models. Confounders will also be analyzed to determine if two variables are highly 
correlated (r>0.7). If two variables have high correlation, the variable that has a stronger 
association with the outcome of this study will be included in the models. Next, we will 
test our unadjusted hypothesis using Chi-squared test for matched subjects with a 
dichotomous outcome (low birth weight). Then, to test our adjusted hypothesis to control 
for confounding factors we will use a conditional logistic regression. Lastly, we will 
analyze secondary outcomes. For spontaneous preterm birth, SGA, and NICU admission, 
all dichotomous outcomes, we will use Chi-squared tests. For Apgar scores, an ordinal 
outcome, we will use paired t-test. To test secondary outcomes while controlling for 
confounding factors, we will use logistic regression for dichotomous secondary outcomes 
and linear regression for ordinal secondary outcomes. All analyses will be conducted 
using SPSS software (SPSS, Chicago, IL). 
 
3.10 Timeline and Resources  
 Our study will be conducted in two years. The first month will be used to identify 
Boston prenatal care practices that are willing to participate in the study. The next 14 
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months will then be used for patient recruitment. Participants will not be recruited in the 
last nine months of the study period because selection during this time risks women 
delivering after the two-year time limit. These last nine months will be used to follow and 
gather information from women previously selected for the study.  
Personnel will include a principal investigator to supervise all phases of the study. 
Under the principal investigator will be two research assistants. Each assistant will be 
assigned to one of the two Boston hospitals. They will be responsible for the women that 
plan to deliver at their assigned hospital. Thus, after a patient is identified by their 
healthcare provider, the research assistant assigned to their intended hospital will 
administer the participant surveys. Two additional assistants will be used to obtain 
neonatal outcomes after delivery. There will be one assistant assigned to each hospital 
that will be blinded to the exposure status of the mother. Personnel will also include one 
physician associate student to assist with data organization, statistical analysis, and 
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CHAPTER 4: CONCLUSION 
4.1 Advantages 
 As an increasing number of women are reporting marijuana use during pregnancy, 
it is imperative to determine the potential risk this exposure has on neonatal outcomes. 
The key advantages of our study are how we address past limitations in research. First, 
our study has a prospective design. This will inherently reduce the limitations of a 
retrospective design. We can create strict exclusion criteria to identify a specific sample 
of pregnant women. Most importantly, our criteria will exclude women with 
polysubstance use. Excluding women with other substance use during pregnancy will 
reduce major confounding factors. This has rarely been achieved in previous research. 
Additionally, a prospective design will reduce recall bias in self-reported drug use. 
Participants will have the resources to report daily marijuana use so it does not have to be 
recalled at each prenatal care visit. Finally, this design will measure marijuana at its 
current potency. Prior studies have analyzed marijuana of lower potency which may not 
have had the same adverse effect.  
 A second advantage will be our method to determine exposure status. Marijuana 
use will be identified with maternal self-report and urine drug screens. We will use urine 
drug screens as an objective measure to reduce the misclassification that could occur 
from using subjective self-report alone. Additionally, conducting our study in Boston 
may reduce social desirability bias. Recreational marijuana legalization may reduce the 
number of women falsely reporting exposure from fear of social or legal consequences. 
This is more likely to occur where recreational marijuana has not been legalized. 
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Lastly, our data collection design is an advantage. Many prior studies were unable 
to collect information on frequency, quantity or timing of marijuana use. We will analyze 
a potential dose-dependent relationship as well as a potential association between 
trimester of use and adverse neonatal outcomes. Our data collection of neonatal outcomes 
will also be enhanced by blinding the researcher to exposure status. This will strengthen 
the internal validity of our study.  
 
4.2 Disadvantages  
 Although our study addresses several limitations in previous research, certain 
limitations remain. First, our study design must be a prospective cohort study rather than 
a randomized control trial. We cannot ethically assign women to an exposure that may 
cause harm. In consequence, we cannot standardize the marijuana consumed among 
participants in the exposure group. In addition to quantity, the potency of marijuana may 
vary among participants and for the same participant over time when using different 
products. Measuring the THC content of the marijuana used by each participant would 
provide a more accurate measure of use, but this is not feasible.  
Second, there are limitations when using self-report. Currently, there is no 
uniform method to collect data on marijuana use. Although standardized and validated 
methods exist for self-reported alcohol and tobacco use,1 these methods are not 
transferable to marijuana. While alcohol and cigarettes have standardized potency and 
quantity in commercially available products, marijuana does not. Marijuana products 
purchased from legal dispensaries have these qualities, but when purchased from non-
regulated sellers it does not. This prevents an accurate measure of marijuana in self-made 
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joints, blunts, or bowls. Until a standardized and validated method is developed for 
marijuana, this will be a limitation in research measuring the quantity of consumption. 
Additionally, there are limitations in our sampling method. We will use 
consecutive convenience sampling at two major hospitals in Boston. A non-random 
sampling method may introduce selection bias and weaken external validity. Another 
potential bias in our data collection may arise from maternal self-report. Although 
marijuana has been legalized in Massachusetts for recreational use, use during pregnancy 
may have a social stigma. This stigma and the fear of consequences may lead to 
underreporting use. Furthermore, sampling from an urban population may reduce the 
generalizability of results. Although we will control for many significant confounding 
factors, it is impossible to control for every potential covariate. There may be residual 
confounding in our study population.  
Daily reporting of marijuana use may lead to participant fatigue. We will reduce 
participant fatigue by using a text message service to obtain patterns of daily use. These 
text messages will prompt participants for data collection. This will reduce fatigue from 
having participants maintain their own daily record to provide at each prenatal care visit. 
Using text messages to collect data will restrict the sample population to women with 
mobile devices, but we do not expect this to considerably limit our sample. It may 
slightly reduce the generalizability of our results.  
Lastly, daily reporting of marijuana use may cause participants to become more 
cognizant of their consumption. This may cause some women to change or reduce their 
previous patterns of use. Unfortunately, this is an unavoidable limitation as recording 
daily consumption is a key advantage in this study to determine a potential dose-
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dependent relationship. We will maintain a non-judgmental environment to reduce 
influencing women’s individual decisions throughout pregnancy. 
 
4.3 Clinical Significance  
Current research on the association between prenatal marijuana exposure and adverse 
neonatal outcomes is inconsistent and limited. We assume marijuana exposure in utero 
negatively impacts neonatal development and can be measured through various outcomes 
at birth. However, given the uncertainty of currently available research, the true risk 
remains unknown. A recent report from 2017 found that 10% of women would increase 
marijuana use during pregnancy if it became legal in their state.2 With expanding 
legalization and increasing use, it is imperative to study potential consequences now 
before a larger population of neonates are potentially put at risk. 
 Initially, our study will bring awareness to these changing patterns of use. Greater 
awareness among providers can enhance drug screening during patient visits to develop a 
more thorough patient history. This is not only important for providers working with 
pregnant populations, but any healthcare field working with women in their reproductive 
years. Marijuana use among women is most frequently reported during childbearing age.3 
Various fields can ultimately provide early education on drug use before women become 
pregnant and present to prenatal care practices. Early intervention is crucial in preventing 
teratogenic exposures in early pregnancy.  
After increasing awareness and emphasizing the magnitude of the population at risk, 
results from our study can improve evidence-based practice recommendations. The 
current ACOG recommendation is to discourage all marijuana use until more evidence 
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becomes available.4 Presently, providers feel uncomfortable making recommendations to 
their patients in the absence of clear evidence.5 If our study can determine the association 
with greater certainty, providers may feel more comfortable educating patients on 
potential risks. This can enhance patient-provider communication. 
Lastly, if our study shows an increased risk of adverse neonatal outcomes, our results 
can support future efforts to reduce marijuana use during pregnancy. Education on 
marijuana use is limited with the conflicting information available. A more reliable study 
could encourage prenatal care practices and outreach programs to provide more robust 
information to women. Interventions to reduce adverse neonatal outcomes can ultimately 
lessen healthcare costs and the resources needed to care for unwell neonates. Reducing 
adverse outcomes early in life can also reduce associated medical complications later in 
life. Conducting our study now will support an early intervention to an increasing public 
health concern. As marijuana use rises, it is crucial to identify the risk during pregnancy 
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a) American Indian or Alaska Native 
b) Asian 
c) Black or African American 




a) Hispanic or Latino 
b) Not Hispanic or Latino 
 
What is your current marital status? 




e) Widow  
 





d) 3 or more 
 
How did you feel when you first found out you were pregnant? 
a) I wanted to be pregnant now 
b) I wanted to be pregnant at a later time 
c) I didn’t want to be pregnant now or at any time in the future 
d) I’m not sure what I wanted  
 
How far along is your pregnancy? ______ weeks’ gestation  
 
How far along were you when you had your first prenatal care visit? ______ weeks’ 
gestation 
 
How many prenatal care visits have you had thus far? ______ 
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Have you had a prior pregnancy with a preterm birth? (Before 37 weeks’ gestation) 
a) Yes 
b) No 
c) I am not sure 
 
Have you had a prior pregnancy with an infant that was born with a low birth 
weight? (<2,500 grams) 
a) Yes 
b) No 
c) I am not sure 
 
What was your body weight right before you became pregnant? ______ pounds 
 
What is your height? _____ feet _____ inches 
 
How much weight have you gained during pregnancy thus far? ______ pounds 
 
How many days a week do you engage in 30 minutes of moderate-intensity aerobic 
exercise? 
a) 5 or more days a week 
b) Less than 5 days a week 
 
What is the highest level of education you completed? (Received a diploma) 
a) Did not complete high school 
b) High School or GED 
c) Higher Education/College 
 








What is the current annual income for your household? ______ 
 
What is the size of your household? (Including yourself) ______ 
 
During your current pregnancy, have you been pushed, tripped, hit, slapped, 
kicked, choked, or physically hurt in any other way by your partner? 
a) Yes 
b) No 
Please complete the Pregnancy Experience Scale below.  
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This scale has 10 items you may find uplifting and 10 items you may find upsetting 
during pregnancy. Please circle the number that corresponds to how you are feeling right 
now.  
 
Pregnancy Experience Scale- Brief 
 
DiPietro et al. 
 
Substance Use History 
 
Since your pregnancy began, have you used marijuana? 
a) Yes  
b) No  
 
Since your pregnancy began, have you consumed alcohol? 
c) Yes  
d) No  
 
Since your pregnancy began, have you used tobacco or nicotine products? 
a) Yes  
b) No  
 
Since your pregnancy began, have you used amphetamines (meth, speed, ecstasy), 
cocaine (coke, crack), opiates (heroin, opium, codeine, morphine), phencyclidine (PCP, 
angel dust), barbiturates (phenobarbital, butalbital, secobarbital, downers), 
benzodiazepines (valium, Librium, Xanax) or methadone? 
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a) Yes  
b) No  
 
If you used a substance during pregnancy not listed in the previous question, please 
indicate it here ______________________. 
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APPENDIX B: Marijuana Use Journal  
 
Marijuana Use Journal (Example Page) 
 
            
Friday January 1, 2021           Identification code: 01234 
 
 
Saturday January 2, 2021            
 
 
Sunday January 3, 2021            
 
 
Monday January 4, 2021            
 
 
In the Marijuana Use box please circle Yes or No for each day. 
 
Please circle the method used on the given day. Please provide a number for the marijuana amount 
consumed. Only record the amount in the column below the method. For cartridges, please provide 












% Cartridge Used:  
 













% Cartridge Used: 25% 
 













% Cartridge Used:  
 













% Cartridge Used:  
 




APPENDIX C: Kotelchuck Index  
 
Adequacy of Prenatal Care Utilization Index 
 
 - Kotelchuck. 1994. 
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APPENDIX D: Participant Consent Form 
 
WRITTEN CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
 
 
Study Title: Prenatal Marijuana Use and Potential Adverse Neonatal Outcomes 
 
Principal Investigator: Tracy Buechele 
 
Affiliation: Yale University School of Medicine, Massachusetts General Hospital & 
Brigham and Women’s Hospital  
 
 
Invitation to Participant and Description of Project 
 
We are inviting you and your baby to participate in a research study designed to look at 
neonatal outcomes at birth. You have been selected because you are 18 years of age or 
older and you have a singleton, uncomplicated pregnancy. Approximately 552 women 
will participate in this study. Half of this sample will be women reporting no drug use 
during pregnancy while the other half will be women using marijuana during pregnancy. 
Neonatal outcomes at birth will be compared between the two groups to see if there are 
differences.  
 
In order to decide whether or not you wish to be a part of this research study you should 
know enough about its risks and benefits to make an informed decision. This permission 
form gives you detailed information about the study, which a member of the research 
team will discuss with you. This discussion should go over all aspects of this research: its 
purpose, the procedures that will be performed and any risks of the procedures. Once you 
understand the study, you will be asked if you wish to participate; if so, you will be asked 
to sign this form. 
 
 
Description of Procedures 
 
If you agree to participating in this observation study, you will be followed by the 
research team throughout your pregnancy to delivery. 
 
▪ Initial participant selection occurs by healthcare providers. You were selected by 
your provider because you meet study criteria and plan to give birth at 
Massachusetts General Hospital or Brigham and Women’s Hospital. If you agree 
to participate, we will confirm your eligibility by reviewing your medical record. 
▪ After signing the consent form, you will be contacted by a researcher to fill out a 
participant survey. This will ask you a number of questions on maternal history, 
social history, demographic information, and substance use history since 
becoming pregnant. This survey will be completed at every prenatal care visit. 
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The purpose of this survey is to gather information that may impact neonatal 
outcomes at birth. 
▪ At each prenatal care visit you will be given a urine drug screen. This will test for 
marijuana, alcohol, nicotine, amphetamines, cocaine, opiates, phencyclidine 
(PCP), barbiturates, benzodiazepines and methadone. Use of any substance 
besides marijuana during your pregnancy will remove you from this study. 
▪ For the sample of women that use marijuana during pregnancy, you will be asked 
to report daily use through our text message service. These messages will record 
frequency and quantity of marijuana use. The purpose of this record is to have 
accurate information on marijuana consumption during pregnancy. 
▪ After your baby’s birth, neonatal records will be obtained from the electronic 
medical record. We will gather your baby’s birth weight, gestational age, Apgar 
scores and if there was intensive care required after birth. These outcomes will be 
compared between non-marijuana exposed and marijuana exposed neonates. 
▪ Your participation in this study will end after neonatal records are obtained.  
▪ All medical decisions will be made by your healthcare provider. Researchers will 
have a non-judgmental observational role only.   
 
You will be told of any significant new findings that are developed during the course of 
your participation in this study that may affect your willingness to continue to participate. 
Research results will not be returned to your doctor. If research results are published, 
your name and other personal information will not be given.  
 
 
Risks and Inconveniences 
 
There are no physical risks associated with this study. Urine drug screens are non-
invasive and will be performed by trained medical professionals. 
 
Recording daily marijuana use may come as an inconvenience to you. Research assistants 
will be available for questions at any time and encourage your full participation.  
 
You may be uncomfortable revealing personal information in participant surveys. Every 
effort will be made to keep your information confidential. A breach of confidentiality is 





This study aims to determine if there are differences in neonatal outcomes at birth from in 
utero marijuana exposure verses no exposure. Although there may be no direct benefit for 
you from your participation, this research will advance our understanding of how 





Participant surveys will be provided free of charge. Urine drug screens should be covered 
by your health insurance, but if not, our study will cover the cost. The text message fees 
should be covered by your cellular service. There are no other costs associated with this 
study so you should experience no financial burden. In addition, completion of this study 
will provide a $25 visa gift card to use at a location of your choice. 
 
 
Confidentiality and Privacy 
 
Any identifiable information that is obtained in connection with this study will remain 
confidential and will be disclosed only with your permission or as required by U.S. or 
State Law. Examples of information that we are legally required to disclose include abuse 
of a child, which we must report to the Department of Children and Families. Information 
will be kept confidential by using only identification numbers on study forms, storing 
signed forms in locked cabinets and password protecting data stored on a computer. 
When the results of the research are published or discussed in conferences, no 
information will be included that would reveal your identity unless your specific 
permission for this activity is obtained. 
 
We understand that information about your health is personal, and we are committed to 
protecting the privacy of that information. If you decide to be in this study, the researcher 
will get information that identifies your personal health information. This may include 
information that might directly identify you, such as name and address, telephone 
number, and email address, or mobile phone number. This information will be de-
identified at the earliest reasonable time after we receive it, meaning we will replace your 
identifying information with a code that does not directly identify you. The principal 
investigator will keep a link that identifies you and your coded information, and this link 
will be kept secure and available only to the principal investigator or selected members of 
the research team. Any information that can identify you will remain confidential. The 
research team will only give coded information to others to carry out this research study. 
The link to your personal information will be kept for 5 years, after which time the link 
will be destroyed and the data will be anonymous. The data will be kept in this 
anonymous form indefinitely.  
 
The information about your health that will be collected in this study includes: 
• Research study records 
• Records about phone calls made as part of this study 
• Records about your study visits 
 
Information about your health may be used by or given to: 
• The U.S. Department of Health and Human Services (DHHS) agencies 
• Representatives from Yale University, the Yale Human Research Protection 
Program and the Yale Human Investigation Committee (the committee that 
reviews, approves and monitors research on human subjects), who are responsible 
for ensuring research compliance. These individuals are required to keep all 
information confidential. 
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• Representatives from the Partners Human Research Committee (the institutional 
review board of Partners HealthCare for Massachusetts General Hospital & 
Brigham and Women’s Hospital that must approve all human-subject research). 
These individuals are required to keep all information confidential. 
• Individuals at Yale who are responsible for the financial oversight of research 
including billings and payments 
• The Principal Investigator 
• Co-Investigators  
• Members of the Research Team 
 
By signing this form, you authorize the use and/or disclosure of the information described 
above for this research study. The purpose for the uses and disclosures you are 
authorizing is to ensure that the information relating to this research is available to all 
parties who may need it for research purposes.  
 
All healthcare providers subject to HIPAA (Health Insurance Portability and 
Accountability Act) are required to protect the privacy of your information. The research 
staff at the Yale School of Medicine are required to comply with HIPAA and to ensure 
the confidentiality of information.  
 
If you choose to participate in this study, the investigators will check your electronic 
medical record through EPIC to make sure you qualify. Any access to your electronic 
medical record will be done consistent with HIPAA regulations.  
 
Some of the individuals or agencies listed above may not be subject to HIPAA and 
therefore may not be required to provide the same type of confidentiality protection. They 
could use or disclose your information in ways not mentioned in this form. However, to 
better protect your health information, agreements are in place with these individuals 
and/or companies that require that they keep your information confidential.  
 
You have the right to review and copy your health information in your medical record in 
accordance with institutional medical record policies. This authorization to use and 
disclose your health information collected during your participation in this study will 
never expire.  
 
 
Voluntary Participation and Withdrawal 
 
You are free to choose not to participate in this study. Your health care outside the study, 
the payment for your health care, and your health care benefits will not be affected if you 
do not agree to participate. However, you will not be able to enroll in this research study 
and will not receive study procedures as a study participant if you do not allow use of 
your information as part of this study. You do not give up any of your legal rights by 
signing this form. 
 
Withdrawing from the Study 
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If you do not become a subject, you are free to stop and withdraw from this study at any 
time during its course.  
 
To withdraw from the study, you can call a member of the research team at any time and 
tell them you no longer want to take part. This will cancel any future appointments.  
 
The researchers may withdraw you from participating in the research if necessary.  
 
If you choose not to participate or if you withdraw it will not harm your relationship with 
your own providers, Yale School of Medicine, Massachusetts General Hospital or 
Brigham and Women’s Hospital.  
 
 
Withdrawing Your Authorization to Use and Disclose Your Health Information 
 
You may withdraw or take away permission to use and disclose your health information 
at any time. You do this by calling or sending written notice to the Principal Investigator.  
 
When you withdraw your permission, no new health information identifying you will be 
gathered after that date. Information that has already been gathered may still be used and 
given to others until the end of the research study, as necessary to ensure the integrity of 
the study and/or study oversight.  
 




We have used technical terms in this form. Please feel free to ask about anything you 
don’t understand and to consider this research and the permission form carefully – as 





I have read (or someone has read to me) this form and have decided to participate in the 
project described above. Its general purposes, the particulars of my involvement and 
possible hazards and inconveniences have been explained to my satisfaction. My 
signature also indicates that I have received a copy of this consent form. 
 







___________________________  __________________ 





___________________________  __________________ 
Signature of Person Obtaining Consent  Date 
 
 
If you have any further questions about this project or if you have a research-related 
problem, you may contact the Principal Investigator, Tracy Buechele. 
 
If, after you have signed this form you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at (203) 432-5919. If you would like to talk with 
someone other than the researchers to discuss problems, concerns, and questions you may 
have concerning this research, or to discuss your rights as a research subject, you may 
contact the Yale Human Investigation Committee at (203) 785-4688.  
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0.209 240    
Rate Difference -0.094 480 0.033 -0.159 -0.029 
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